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 A physiologically based pharmacokinetic model for tramadol administration in horses 
 Horse physiological processes and elimination pathways are accurately simulated 
 Individualized treatment of anesthesia in horses 
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Abstract 
This work proposes an application of a minimal complexity physiologically based pharmacokinetic 
model to predict tramadol concentration vs time profiles in horses. Tramadol is an opioid analgesic 
also used for veterinary treatments. Researchers and medical doctors can profit from the application 
of mathematical models as supporting tools to optimize the pharmacological treatment of animal 
species. The proposed model is based on physiology but adopts the minimal compartmental 
architecture necessary to describe the experimental data. The model features a system of ordinary 
differential equations, where most of the model parameters are either assigned or individualized for 
a given horse, using literature data and correlations. Conversely, residual parameters, whose value 
is unknown, are regressed exploiting experimental data. 
The model proved capable of simulating pharmacokinetic profiles with accuracy. In addition, it 
provides further insights on un-observable tramadol data, as for instance tramadol concentration in 
the liver or hepatic metabolism and renal excretion extent. 
 
 
 
Keywords: PBPK model; QSP; Tramadol; Horse; Analgesia. 
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1 Introduction 
The knowledge of pharmacokinetic properties of drugs is fundamental to guarantee an effective and 
safe therapeutics administration. This is important for every drug and is required information in 
reports submitted to regulatory agencies for products approval. Analgesic administration is 
particularly critical because the definition of a correct dosage is not universal but should be chosen 
for every patient. In addition, a constant, real-time monitoring of sedation state is necessary. This is 
achieved by controlling some pharmacodynamic parameters and adapting the analgesic 
administration accordingly, to maintain the subject in the optimal sedation state. Pharmacodynamic 
parameters are partial indicators of sedation state, allow an indirect and approximated guess of 
analgesic blood levels, and help anesthetists adapting the dosage based on their experience. 
The only possibility to quantify the actual analgesic concentration is blood sampling and the drug 
concentration essay. Clearly, this comes with several difficulties and limitations, and is not always 
possible. A valid alternative is the exploitation of mathematical models to predict drug 
concentration levels. Numerical simulations allow the generation of drugs’ blood concentration vs 
time profiles (model output) given an administration route and dosage (model input). 
This work focuses on tramadol, an analgesic drug extensively used for both clinical and non-clinical 
applications, and proposes a pharmacokinetic (PK) model for the assessment and prediction of 
tramadol blood concentration in horses. There are two past activities that led to the realization of 
this work: one has an empirical nature and is linked to studies on tramadol administration in horses 
(Cagnardi et al., 2014), the other is based on research on PK mathematical models (Abbiati et al., 
2016). The joint activity of these research groups is summarized in this paper and is an example of 
the convergence of different knowledges in the emerging discipline of quantitative systems 
pharmacology. 
A PK model based on a mechanistic approach, named physiologically based pharmacokinetic 
(PBPK) model, is applied for the in silico reproduction (i.e. computer simulation) of tramadol 
concentration vs time profiles in horses. In particular, we propose a minimal complexity PBPK 
model, this means that the compartmental structure of the model is reduced in accordance with the 
limited experimental information available. The compartmental formulation of PBPK models is 
based on the hypothesis of perfectly mixed compartments. Every compartment is assumed as a 
heterogeneous volume, whose dimensions are comparable to the related body counterpart, see 
(Abbiati et al., 2016) for further details on mathematical and model-related matters. 
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1.1 Tramadol in horses and PK modeling 
In veterinary species, the principles of anesthesia and analgesia are based on different drug 
administrations. In horse practice, the patient is pre-medicated with sedatives or tranquillizers to 
decrease the attention level and external stimuli response, induced into an unconsciousness level 
with hypnotic anesthetic drugs, and then the anesthesia can be maintained with inhalation 
anesthetics. To prevent nociception during surgery and achieve a stable anesthetic depth, analgesic 
drugs can be administered before surgery start, as pre-emptive treatment (Miur and Hubbel, 2009). 
In veterinary medicine, PBPK models can predict tissue concentrations of active principles and their 
potential metabolites after complex exposures, and are powerful in extrapolating dosage schemes 
across species. Thus, PBPK models have been widely used in predictive risk assessment for a 
variety of environmental contaminants in laboratory-animals and humans, and in estimating tissue 
residues and withdrawal times for drugs in food animals (Lin et al., 2016). 
The use of PBPK models is quite limited in horse. Indeed, two studies were published so far, by the 
same group of researchers, with the aim of evaluating amiodarone or ketamine pharmacokinetics in 
ponies (Knobloch et al., 2006; Trachsel et al., 2004). 
As far as tramadol is concerned, there are not any PBPK models available in veterinary species. In 
horse, its PK profiles, following different routes, dosage schemes, and with different formulations 
was widely studied with classical non-compartmental and compartmental analyses, but at our 
knowledge it was not simulated with PBPK modeling. 
1.2 Tramadol 
Tramadol, is a synthetic opioid analogue to morphine and codeine. In humans, it is commonly used 
as an analgesic drug for acute and chronic pain treatment, so as for moderate to severe post-
operative pain. It has a low incidence of adverse effects, i.e. respiratory depression, constipation and 
abuse potential, and is not a controlled drug (Grond and Sablotzki, 2004; Scott and Perry, 2000). 
Tramadol is also used in companion animal veterinary practice for pain management. Since the first 
report of its analgesic effect in horses after epidural administration by Natalini and Robinson 
(2000), tramadol has been introduced in equine practice as analgesic drug for moderate to severe 
pain, and pharmacokinetic and efficacy studies (Dhanjal et al., 2009; Knych et al., 2016; Shilo et 
al., 2008; Stewart et al., 2011). Tramadol is administered both orally and parenterally. The 
intravenous dose is extrapolated from human or other species data and ranges from 3 to 5 mg/kg 
BW, with the consequent uncertainties associated to this practice. 
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Tramadol undergoes extensive first-pass metabolism in the liver, via two main metabolic pathways 
involving cytochrome P450 isoenzymes CYP3A and CYP2D6 (Scott and Perry, 2000). The major 
metabolites present in human plasma are O-desmethyltramadol (M1) and N-desmethyltramadol 
(M2), and to a minor extent N,N-didesmethyltramadol (M3), N,N,O-tridesmethytramadol (M4) and 
N,O-desmethyltramadol (M5) (Grond and Sablotzki 2004). M1 formation is mediated by CYP2D6, 
whereas M2 is produced by CYP3A4 and CYP2B6. Tramadol and its metabolites are almost 
completely excreted via the kidneys and approximately 10 to 30% of the parent drug is excreted 
unmetabolised in the urine (Grond and Sablotzki, 2004; Scott and Perry, 2000). These indications 
are consistent with NIH (2017) data on tramadol elimination, where approximatively 30% is 
eliminated unmodified by kidneys, while 60% is a product of hepatic metabolism. M1 is the main 
analgesic effective metabolite with a more potent -receptor effect than the parent compound and 
its formation occurs at different rates in veterinary species (Cagnardi et al., 2011; Knych et al., 
2013; Kukanich and Papich, 2004). In horse, M1 formation seems to be catalyzed by the CYP2D50 
enzyme, the equine orthologue to human CYP2D6 (Corado et al., 2016). 
2 Methods 
The experimental data on tramadol PK in horses are available in Cagnardi et al. (2014), with horses 
data synthetically reported in Table 1. 
Table 1 – Horse ID, Breed, and Body Weight summary (Cagnardi et al., 2014). The original study reported 8 horses 
but one was later excluded due to issues related to blood withdrawals (see missing Horse ID = 4). 
Patient Horse ID Breed Body Weight (kg) 
1 1 Arabian 292 
2 2 Arabian 336 
3 3 Arabian 324 
4 5 Arabian 303 
5 6 Arabian 323 
6 7 Thoroughbred 431 
7 8 Quarter Horse 490 
Eight horses undergoing orchiectomy received, as a pre-emptive analgesic, an intravenous (IV) 
injection of 4 mg/kg tramadol administered in 60 s, 15 min before surgery, which lasted 20 min. 
The anesthetic protocol for each horse included: intramuscular acepromazine maleate (0.05 mg/kg 
BW) and detomidine (range 0.01-0.02 mg/kg BW), as pre-anesthetic medications; IV ketamine (2.2 
mg/kg BW) and diazepam (0.05 mg/kg BW) for general anesthesia induction; isoflurane in oxygen 
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(100%) for maintenance. Only the pharmacokinetics of tramadol and its metabolites was monitored 
in blood and urine. Eleven blood samples were collected at 0.08, 0.16, 0.33, 0.5, 0.75, 1, 1.5, 2, 4, 8, 
and 10 h post administration. 
The adopted PBPK model is the one from (Abbiati et al., 2016), which is a lumped model based on 
the approach of minimal complexity (Cao and Jusko, 2012). This model was further lumped due to 
the limitation of experimental data: the original model considers two distribution compartments, the 
former for the highly perfused organs and the latter for the poorly perfused tissues. Despite this 
assumption can be important in case of availability of experimental drug concentration in tissues, as 
proved in Abbiati et al. (2015), we considered inappropriate such a differentiation for the present 
case as only plasma PK is known. For this simulation, a single compartment for general site of drug 
distribution was used and named “Tissues”. Figure 1 shows the actual model compartmental 
structure, which features four compartments. 
 
Figure 1: Structure of the lumped PBPK model. Tramadol is administered endovenous (IV) to Plasma compartment. 
Systemic circulation delivers the drug to the Tissues compartment, which represents a general distribution volume, and 
to the Liver. Tramadol reaches the Liver directly via the hepatic artery and GICS, which is the vasculature located in 
the mesentery. Drug is eliminated at different extents via liver metabolism (CL
H
) and by the kidneys (CL
K
). 
The model eq.s (1 - 4) are: 
 
     
 
 
(1 )
P HA PV T HV
P T L
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 
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( )P Tf j  ( )T Pf j 
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 
     
L HV H HA PV
L P GICS
L L L L
dC t Q CL Q Q
C t C t C t
dt V V V V
 
     
 
 (4) 
Eq. (1) refers to the Plasma compartment (integration variable: C
P
), eq. (2) to the Tissues 
compartment (integration variable: C
T
), eq. (3) to the Gastro Intestinal Circulatory System or GICS 
(integration variable: C
GICS
), and eq. (4) to the Liver compartment (integration variable: C
L
). Here, 
     and      are respectively the drug mass transfer coefficients in and out of the Tissues 
compartment, whilst   is the fraction of the drug which is bound to plasma proteins. 
Clearance terms (eq.s (5) and (6)) are calculated as the product of organ’s plasma flow multiplied 
by the clearance efficiency, whose values are reported respectively in Table 2 and Table 3. 
CL
H 
= Q
PV
·Eff
H
 (5) 
CL
K 
= Q
K
·Eff
K 
(6) 
The model features a system of ordinary differential equations, which are integrated with the ode45 
solver of Matlab R2015a, i.e. a single step solver based on an explicit Runge-Kutta (4
th
-5
th
 order) 
formula (Shampine and Reichelt, 1997). 
Model parameters assignment follows the methodology detailed in Abbiati et al. (2016). There are 
three major categories of model parameters: Individualized, Assigned, and Unknown. 
The Individualized parameters are determined with literature correlations based on known physical 
properties. Here parameters as blood flow rate (Q) and compartment volumes (V) are calculated as a 
function of individual horse body weight, as shown in Table 2. 
Table 2 – Individualized parameters, the “Value” column is provided as an example and refers to horse ID 1 of Table 1 
(BW = 292 kg). Density is in [g/cm
3
]. 
Parameter Description Formula Value Units Reference 
CO Cardiac Output † 74·BW 21,608 cm3/min 
(Fisher and Dalton, 
1959) 
Q
HA
 
Hepatic artery 
blood flow 
30 % · 25 % · CO 972 cm
3
/min  (Drivers, 2015) 
Q
PV
 
Portal vein blood 
flow 
70 % · 25 % · CO 2,268 cm
3
/min (Drivers, 2015) 
Q
HV
 
Hepatic vein 
blood flow 
Q
HA
 + Q
PV
 3,241 cm
3
/min 
 
Q
K
 
Kidneys blood 
flow 
17.5 % · CO 2,268 cm
3
/min (Toribio, 2007) 
V
GICS
 GICS volume 1.7725 · BW 517 cm
3
 Patton et al. (2006)† † 
V
L
 Liver volume ††† 3,527 cm3 Staddon et al. (1984) 
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 BW % Density 
Liver 1.3 1.076 
V
T
 Tissues volume 
††† VFat + VBones + VHeart + 
+ VSkin + VMuscles 
171,110 cm
3
 Staddon et al. (1984) 
 BW % Density 
Fat 5.06 0.929 
Bones 10.3 1.68 
Heart 0.66 1.06 
Skin 7.41 1.09 
Muscles 40.14 1.065 
V
P
 Plasma Volume 
†††† 60 % · VBlood 
14,350 mL Staddon et al. (1984)  BW % Density 
Blood 8.6 1.05 
† CO varies dramatically with horse physical activity. We assumed a horse in rest status as expected in case of 
tramadol administration for surgery intervention. 
†† VGICS was not found in the literature. We propose to calculate it according to geometrical considerations. 
Length and diameter of the portal vein of a horse are approximatively 23 cm and 4 cm (Patton et al., 2006), to 
account for the complete mesenteric circulatory system we increased these value by 35% and, assuming the 
portal vein as a cylinder, its volume would be 710 cm
3
. Dividing it by the average weight of a horse (400 kg), 
we obtain the portal vein volume per kilogram of body weight (ω = 1.77 cm3/kg). 
††† The volume of the organs is calculated with eq. (7): 
       
                
                   
      (7) 
where SpecificWeightorgan is Densityorgan/1000. 
†††† Plasma/serum was assumed as 60% of blood volume. (Tranquilli et al., 2007)  
The category “Assigned parameters” refers to known values that cannot be individualized for a 
specific horse; instead, their values are considered constant for any subject. Tramadol, as many 
other drugs, has tendency to bind plasma proteins. This has profound and direct consequences on 
drug distribution extent. Our model accounts for this aspect with R parameter, which quantifies 
tramadol fraction bound to plasma proteins, being 19.5 - 20% (i.e. R = 0.2 in eq.s (1-4)) as in 
(Cagnardi et al., 2014), (Lee et al., 1993) and (Abbiati et al., 2016). 
Finally, this model considers four Unknown parameters (i.e. jP-T, jT-P, Eff
H
, Eff
K
). These parameters 
cannot be found in the literature, in part because they are very specific tissue properties and in part 
because they are mathematical terms without a direct physical counterpart. For example, the jP-T 
term represents the mass transport coefficient of tramadol from vasculature to the generic Tissues 
compartment. It depends on a number of biological and physical tissue properties, as vasculature 
fenestration size, blood flow velocity at the various capillary diameters, interstitial liquid and 
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extracellular matrix properties, just to cite a few. In addition, since Tissues is a lumped 
compartment, it accounts for a number of tissues with very different properties. Consequently, a 
direct assessment of these parameter values is unfeasible, and we decided to regress them by using a 
suitable set of experimental data of tramadol PK in horses. 
The mathematical model for the regression procedure is the one defined in eq.s (1-4), Individualized 
and Assigned parameters were given as calculated above, while the Unknown parameters were 
initialized with first-guess values. The experimental data for the regression procedure are the ones 
from Table 1 for ID 6, 7, and 8 horses. 
The non-linear regression minimizes an objective function defined as the sum of residuals (SR) 
between experimental measures and model predictions. The SR definition is a fundamental 
prerequisite for a successful regression. We adopted a logarithmic formulation in order to equalize 
the contributions of SR. In addition, we added two terms to account for the clearance pathways. In 
Section 1.2 “Tramadol”, we discussed tramadol PK and highlighted that drug elimination occurs for 
about 60% of the dose as hepatic metabolism, for 30% as renal excretion, while the residual 10% 
can be ascribed to other delocalized tissues metabolism. At the purpose of parameters regression 
and as a function of the lumped PBPK model, to efficiently determine parameters such as CL
H
 and 
CL
K
, we imposed that tramadol eliminated via liver metabolism (CL
H
) accounts for 66% (i.e. 
     
 ), while tramadol eliminated via kidneys (CL
K
) accounts for 34% (i.e.      
 ). By doing so, 
we arbitrarily neglected the previously cited 10% of tissues metabolism at the purpose of keeping 
the number of model parameters limited. Indeed, we redistributed this contribution between liver 
and kidneys. The last two terms of SR in eq. (8) enhance the physiological attributes of the 
mathematical model. 
       
   
10 exp, , 10 , , 10 10 ,
10 10 ,
log log log log ( )
log log ( )
NS
H
NP j i model j i i MAX H i fin
j
i K
i MAX K i fin
C C Dose EL Emass t
SR
Dose EL Emass t
  
      
   
 
   
 

 (8) 
Here, NP is the number of patients with index i, and NS is the number of blood samples collected 
with index j. Cexp is the experimental measure of tramadol concentration, Cmodel is the corresponding 
model calculated one. Dose is the total administered dose, EmassH(tfin) is the cumulated value of the 
liver-metabolized mass at the final time of simulation tfin, EmassK(tfin) is the cumulated value of the 
kidneys-eliminated mass at tfin. The regression was performed using the fminsearch routine of 
Matlab R2015a, based on the modified simplex method of Lagarias et al. (1998). 
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Table 3 – Unknown parameter values, determined via the non-linear regression. 
Parameter Description Value Units 
Standard 
Deviation 
Confidence 
Interval (95%) 
jP-T Plasma to Tissues mass transfer coefficient 0.108 min
-1
 0.0027 3.73·10
-4
 
jT-P Tissues to Plasma mass transfer coefficient 0.0125 min
-1
 0.0003 4.24·10
-5
 
Eff
H
 Hepatic efficiency of elimination 0.618 - 0.0161 2.24·10
-3
 
Eff
K
 Kidneys efficiency of elimination 0.225 - 0.0059 8.02·10
-4
 
Once the whole set of model parameters is determined, the model was validated by running distinct 
in silico simulations of the remaining subjects (i.e. horse IDs 1, 2, 3, and 5). Input data were the 
administered dose and the horse BW. The Individualized parameters were calculated according to 
the previous described correlations of Table 2, while the Assigned and Unknown parameters were 
kept the same for every horse. Eventually, simulation results were compared to experimental data. 
3 Results and Discussion 
The PBPK model was simulated and compared to the experimental measures. Figure 2 shows the 
tramadol PK simulation for the representative horse ID 5 as all the other simulations show 
comparable simulated PK profiles. The concentration vs time drug profile displays a rapid increase 
of tramadol concentration, which reaches the peak value at the end of injection (1 min post 
administration start). Tramadol goes through a rather rapid distribution process from the central 
compartment (i.e. Plasma) to the Tissues compartment, which acts as a reservoir site. From the 
peripheral compartment (Tissues) the drug returns to the central one, where it is eliminated via renal 
excretion. This produces the two-phase decline, which is evident in the semi-log plots of Figure 2. 
The first phase lasts 25 min post administration with a rapid tramadol distribution, followed by a 
second elimination phase with slower kinetics. 
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Figure 2: Model validation by comparison with the experimental data (ID 5 horse). 
This lumped PBPK model shows a general behavior of a bi-compartmental model, which is the 
two-phase decline, as expected from the presence of two major compartments (i.e. Plasma and 
Tissues) that are in direct relation. In addition, it introduces other advantages: it allows the 
simulation of tramadol PK in sites other than plasma (Figure 3) and it clearly differentiates the 
elimination process in terms of hepatic metabolism and renal excretion (Figure 4). For the sake of 
precision, the elimination term for liver metabolism refers to the disappearance of tramadol 
molecules to give metabolites. The simulated profiles of Figure 4 are important because of the 
extensive P450 cytochrome metabolic activity. The accurate formulation of the SR objective 
function (eq. (8)) allows quantifying each of these elimination routes. Figure 4 evidences that nearly 
the entire tramadol dose is eliminated in 10 h and is found in the urine, 2/3 as metabolites and the 
remaining excreted unmodified. 
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Figure 3: Model simulation of tramadol concentration in the Liver compartment. This is an un-observable compartment 
from an experimental viewpoint, unless tissue samples are dynamically collected. This practice is complex and usually 
limited by sensible and ethical constraints. In this perspective, modeling is a necessary instrument for quantitative 
systems pharmacology. 
 
Figure 4: Tramadol elimination by the two physiological routes: hepatic and renal. Left vertical axis reports tramadol 
mass [µg], right vertical values are the normalized mass fractions respect to the administered dose. Dashed lines 
represent the expected eliminations by the respective mechanisms: blue (0.66) for liver metabolism and red (0.34) for 
kidneys elimination. Continuous lines are the model simulated profiles of cumulated eliminated mass: blue for liver 
metabolism and red for kidneys elimination. 
Figure 2 shows that the model prediction is in good agreement with the experimental data, as the 
concentration vs time curve of tramadol falls within the standard deviation bars for most of the 
Hepatic
Renal
Total
0.66
1
0.34
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experimental data. To provide a numerical quantification of the pharmacokinetic curve quality we 
adopted the prediction error coefficient (   in eq. (9) and Table 4). This parameter quantifies the 
normalized difference of model concentration respect to the experimental one, divided by model 
concentration at the j-th sampling time. 
     
  
         
   
  
      (9) 
Table 4 – PE values at each blood withdrawal time. The time is exactly the one of the withdrawal. That is why it might 
slightly be different from the declared ones. Data are reported for horse ID 5, others show similar PE median values. 
Time [min] 5 10 20 30 45 60 85 116 245 480 600 
PEj 0.254 0.465 0.1663 0.448 0.560 0.102 0.161 0.002 0.183 0.984 0.991 
The reference parameter is the median of this PE, which is equal to 0.25. This value is strongly and 
negatively affected by the last two samples (at 480 and 600 min). Here the tramadol concentration 
is practically negligible, but since PE is based on a normalized value, it produces errors close to 
100%. If these two data were neglected the median PE would drop to 0.18. 
4 Conclusions 
Analgesic therapies can gain profit from the use of PBPK models since numerical predictions allow 
forecasting un-observable drug concentration levels. Additionally, since dosage can be varied due to 
patient response or physician necessity, the use of a robust model allows the instantaneous re-
evaluation of the expected drug concentration-time profile. The predictive capability of the PBPK 
model paves the way to a model-based approach to anesthesia control (e.g., Model Predictive 
Control), as the individualized patient’s response can be evaluated in silico and tuned to meet the 
optimal trajectory of anesthesia treatment as a function of the (dynamically) administered dose.  
The patient’s response to the administered treatment is a feedback signal (input) for the on-line 
control unit, which determines any necessary corrections to the administered dose via a dynamical 
model adaptation (Abbiati and Manca, 2016). 
The minimal-PBPK model presented in this work has the advantage to preserve a physiological 
correspondence with the administration of tramadol in horse (see the set of individualized 
parameters in Table 2, or the structure of Figure 1 where the Liver compartment and metabolism are 
explicitly considered). The physiological correspondence allows identifying specific processes of 
drug distribution and elimination. Furthermore, only PBPK models can be adapted to predict PK of 
other species. 
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Since experimental data of drug concentration were measured just in serum, tissues concentration 
were not available. Therefore, complex full-body PBPK model, which are commonly used, do not 
permit a robust identification of regressed (Unknown) model parameters. This is why we promote 
the application of models whose complexity is balanced on experimental data availability. 
Finally, this model was applied to run tramadol simulations in horses and showed good consistency 
with experimental data. Consequently, this model with its parameters set (Table 2 and Table 3) is 
suitable for further simulations of tramadol in horse. Veterinary practice can profit from the use of 
this model by reducing operative times and costs. 
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